ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/QLD/4575-Birtinya-Sunshine-Coast-University-Hospital
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
29
trial(s) found.
NCT07042100
Advanced
Phase 1
Not yet recruiting
A Phase 1, Multicentre, Open-label, Multiple-dose Study to Determine Safety, Tolerability, and Preliminary Efficacy of SBO-154 in Subjects With Advanced Solid Tumors (
SBO-154-25-01
)
anti-MUC1 antibody-drug conjugate
Solid tumour
QLD
4575 - Birtinya - Sunshine Coast University Hospital
NCT06943872
Haem
Phase 3
Recruiting
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (
BGB-11417-303
)
Bcl2 inhibitor
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2109 - North Ryde - Macquarie University Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2217 - Kogarah - St George Hospital
2480 - Lismore - Lismore Base Hospital
2500 - Wollongong - Wollongong Private Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4575 - Birtinya - Sunshine Coast University Hospital
WA
6005 - West Perth - Perth Blood Institute
6168 - Cooloongup - Rockingham Hospital
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06921837
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, First-in-Human, Dose Escalation and Expansion Study of BDC-4182 as a Single Agent in Patients With Advanced Gastric and Gastroesophageal Cancer (
BBI-4182-101
)
anti-CLDN18.2 immune-stimulating antibody conjugate,TLR7/8 agonist
Adenocarcinoma
Gastric cancer
Gastroesophageal junction adenocarcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
NCT06890598
Curative
Phase 3
Recruiting
A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer -
SUNRAY-02
KRAS G12C inhibitor
placebo
Non-small cell lung cancer
NSW
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3630 - Shepparton - Goulburn Valley Health
3844 - Traralgon - Latrobe Regional Hospital
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4575 - Birtinya - Sunshine Coast University Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06868199
Advanced
Phase 1 / Phase 2
Not yet recruiting
A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours (
LM168-01-101
)
anti-PD-1 monoclonal antibody
unknown drug class
Solid tumour
NSW
2500 - Wollongong - Wollongong Hospital
QLD
4575 - Birtinya - Sunshine Coast University Hospital
NCT06742996
Haem
Phase 3
Recruiting
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma (
BGB-11417-302
)
BTK inhibitor
Bcl2 inhibitor
placebo
Mantle cell lymphoma
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6005 - West Perth - Perth Blood Institute
6009 - Nedlands - Linear Clinical Research
6009 - Nedlands - One Clinical Research
6168 - Cooloongup - Rockingham Hospital
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NZ.9016 - Dunedin - Dunedin Hospital
NCT06357533
Advanced
Phase 3
Recruiting
A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (
TROPION-Lung10
)
anti-PD-1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
bispecific PD-1/TIGIT antibody
Non-small cell lung cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
3690 - Wodonga - Border Medical Oncology at Wodonga Regional Cancer Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
4215 - Southport - Gold Coast University Hospital (WITHDRAWN)
NCT06356129
Haem
Phase 3
Recruiting
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants With Previously Untreated High-risk Large B-cell Lymphoma (
GOLSEEK-1
)
CELMoD agent
placebo
Diffuse large B-cell lymphoma
NT
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit
QLD
4215 - Southport - Gold Coast University Hospital
4575 - Birtinya - Sunshine Coast University Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.9016 - Dunedin - Dunedin Hospital
NCT06152575
Haem
Phase 3
Recruiting
A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE (PVd) OR CARFILZOMIB, DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTI-CD38 DIRECTED THERAPY (
C1071032
)
anti-CS1 monoclonal antibody
bispecific T-cell engager,BCMA-targeting
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
NSW
2139 - Concord - Concord Repatriation General Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3066 - Epping - Northern Hospital
QLD
4575 - Birtinya - Sunshine Coast University Hospital
NCT06119581
Advanced
Phase 3
Recruiting
SUNRAY-01
, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression
KRAS G12C inhibitor
anti-PD-1 monoclonal antibody
antimetabolite
placebo
Non-small cell lung cancer
NSW
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3630 - Shepparton - Goulburn Valley Health
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4215 - Southport - Gold Coast University Hospital
4575 - Birtinya - Sunshine Coast University Hospital
4740 - Mackay - Mackay Base Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06018337
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Multi-center, Open-Label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (
DB-1303-O-3002
)
anti-ERBB2 antibody-drug conjugate
Breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4215 - Southport - Gold Coast University Hospital
4575 - Birtinya - Sunshine Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT05923008
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Multicenter, Open-label Study of IBI130 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors (
CIBI130A101
)
anti-Trop2 antibody-drug conjugate
anti-Trop2 monoclonal antibody
Solid tumour
QLD
4575 - Birtinya - Sunshine Coast University Hospital
NCT05914116
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects With Advanced/Metastatic Solid Tumors (
DB-1311-O-1001
)
anti-B7H3 antibody-drug conjugate
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2228 - Miranda - Southside Cancer Care Centre
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2305 - New Lambton Heights - John Hunter Children's Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05886868
Advanced
Phase 1
Recruiting
A Phase I, International, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of BL0020 as A Single Agent in Patients With Advanced Solid Tumors (
BL0020-101
)
unknown drug class
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
QLD
4575 - Birtinya - Sunshine Coast University Hospital
NA
NA
NCT05774951
Curative
Phase 3
Recruiting
CAMBRIA-1
: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence
selective estrogen receptor degrader
selective estrogen receptor modulator
Breast cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2139 - Concord - Concord Repatriation General Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2485 - Tweed Heads - The Tweed Hospital
VIC
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (WITHDRAWN)
NCT05519085
Haem
Phase 3
Recruiting
A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM):
SUCCESSOR-1
cereblon E3 ligase modulator
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
NSW
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2500 - Wollongong - Wollongong Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.9016 - Dunedin - Dunedin Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (WITHDRAWN)
NCT05393791
Advanced
Phase 2
Recruiting
ANZadapt
: Phase II Randomised Controlled Trial of Patient-specific Adaptive Versus Continuous Abiraterone or eNZalutamide in Metastatic Castration-resistant Prostate Cancer
CYP17A1 inhibitor
antiandrogen,nonsteroidal,second generation
Castrate-resistant prostate cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - GenesisCare North Shore Private Hospital
2076 - Wahroonga - Sydney Adventist Hospital
2217 - Kogarah - St George Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2640 - Albury - Albury Wodonga Regional Cancer Centre
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05243797
Haem
Phase 3
Recruiting
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation -
MajesTEC-4
bispecific T-cell engager,BCMA-targeting
immunomodulatory imide drug
Multiple myeloma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4575 - Birtinya - Sunshine Coast University Hospital
4575 - Sunshine Coast - Sunshine Coast University Private Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
NCT05199753
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours (
LM108-01-101
)
anti-CCR8 monoclonal antibody
Solid tumour
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - One Clinical Research
NCT04975997
Haem
Phase 3
Recruiting
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) (
EXCALIBER-RRMM
)
CELMoD agent
anti-CD38 monoclonal antibody
glucocorticoid
proteasome inhibitor
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
ACT
2605 - Garran - The Canberra Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics
6150 - Murdoch - Fiona Stanley Hospital
NCT04964518
Haem
Phase 1 / Phase 2
Recruiting
A Phase Ib/II Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML), Mixed Phenotype Acute Leukemia (MPAL), Chronic Myelomonocytic Leukemia (CMML) and Higher-Risk Myelodysplastic Syndrome (MDS (
APG2575AU101
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
antimetabolite
Solid tumour
VIC
3066 - Epping - Northern Hospital
QLD
4217 - Benowa - Pindara Private Hospital
4575 - Birtinya - Sunshine Coast University Hospital
WA
6000 - Perth - Royal Perth Hospital
NCT04332822
Haem
Phase 3
Recruiting
R-MINI-CHOP Versus R-MINI-CHP in Combination With Polatuzumab-vedotin, as Primary Treatment for Patients With Diffuse Large B-cell Lymphoma, ≥80 Years, or Frail ≥75 Years - an Open Label Randomized Nordic Lymphoma Group Phase III Trial (
POLAR-BEAR
)
anti-CD79b antibody-drug conjugate
Diffuse large B-cell lymphoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2487 - Cudgen - Tweed Valley Hospital
2640 - Albury - Albury Wodonga Regional Cancer Centre
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
ACT
2605 - Garran - The Canberra Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3065 - Fitzroy - St Vincent's Hospital Melbourne
3066 - Epping - Northern Hospital
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6000 - Perth - Royal Perth Hospital
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
ACTRN12623000956606
Advanced
Phase 1
Recruiting
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacology, and Preliminary Efficacy of AT-0174 in Subjects with Advanced Solid Malignancies (
Australia
)
dual IDO/TDO inhibitor
Solid tumour
NSW
2228 - Miranda - Southside Cancer Care Centre
VIC
3066 - Epping - Northern Hospital
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
ACTRN12622001366741
Haem
Phase 2
Recruiting
Investigating the efficacy of Risk Directed front-line therapy for Multiple Myeloma incorporating Selinexor: The
RIDDLE-M-X
trial
XPO1 inhibitor
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2640 - Albury - Border Medical Oncology Research Unit
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
ACTRN12622000973718
Advanced
Phase 2
Recruiting
SHERLOCK
: Phase 2 trial of sotorasib in combination with carboplatin-pemetrexed and bevacizumab-biosimilar as first line treatment for advanced non-squamous non-small cell lung cancer with KRAS G12C mutation
KRAS G12C/NRAS G12C/HRAS G12C inhibitor
KRAS G12C inhibitor
anti-VEGF monoclonal antibody
antimetabolite
platinum-based antineoplastic agent
Non-small cell lung cancer
Non-squamous non-small-cell lung cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2086 - Frenchs Forest - Northern Beaches Hospital
2170 - Liverpool - Liverpool Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - The Prince Charles Hospital
4575 - Birtinya - Sunshine Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
ACTRN12620000757910
Radonc
Not Applicable
Recruiting
Functional imaging-guided radiotherapy dose escalation in rectal adenocarcinoma: a feasibility study (
FIGURE-rectal
)
radiotherapy
Rectal adenocarcinoma
QLD
4575 - Birtinya - Sunshine Coast University Hospital
NCT06497556
Advanced
Phase 3
Not recruiting
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients With Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (
Krascendo-1
)
KRAS G12C/NRAS G12C/HRAS G12C inhibitor
KRAS G12C inhibitor
Non-small cell lung cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - GenesisCare North Shore Private Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
NCT05805501
Advanced
Phase 2
paused
A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma (
BO43936
)
KIT inhibitor,ATP-competitive
VEGFR/PDGFR inhibitor
Clear cell renal cell carcinoma
QLD
4575 - Birtinya - Sunshine Coast University Hospital
ACTRN12625000311459
Radonc
Not Applicable
Active not recruiting
Effect of Functional Imaging Guided Salivary Gland Sparing Radiation Therapy on Xerostomia Toxicity and Quality of Life in Adults with Primary Carcinoma of the Head and Neck Region. (
FIGS-RT
)
radiotherapy
Head and neck cancer
QLD
4575 - Birtinya - Sunshine Coast University Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (24)
Not yet recruiting (2)
Not recruiting (1)
paused (1)
Active not recruiting (1)
Recruitment Country and State
QLD (29)
NSW (23)
VIC (20)
WA (12)
SA (9)
NZ (5)
ACT (2)
TAS (2)
NT (1)
Phase
Phase 1 (3)
Phase 1 / Phase 2 (6)
Phase 2 (4)
Phase 3 (14)
Trial Type
Advanced (15)
Haem (10)
Curative (2)
Radonc (2)
Cancer Therapy Class
cereblon
21%
PD-1
17%
PD-1/PD-L1
17%
KRAS
14%
KRAS G12C
14%
proteasome
14%
Bcl2
10%
CD20
10%
TIGIT
7%
Trop2
7%
BCMA
7%
HRAS G12C
7%
NRAS G12C
7%
CLDN18.2
3%
PD-L1
3%
BTK
3%
CS1
3%
ERBB2
3%
B7H3
3%
ER
3%
oestrogen axis
3%
AR
3%
CYP17A1
3%
androgen axis
3%
CCR8
3%
CD38
3%
DNA methyltransferase
3%
CD79b
3%
IDO
3%
TDO
3%
XPO1
3%
VEGF
3%
KIT
3%
LAG3
3%
PDGFR
3%
VEGFR
3%
Facility
4575 - Birtinya - Sunshine Coast University Hospital (29)
3004 - Melbourne, Southbank - Alfred Health (6)
2139 - Concord - Concord Repatriation General Hospital (6)
2050 - Camperdown - Chris O'Brien Lifehouse (6)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (6)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (5)
3065 - Fitzroy - St Vincent's Hospital Melbourne (5)
3168 - Clayton - Monash Medical Centre (5)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (5)
3066 - Epping - Northern Hospital (5)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (5)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (5)
2170 - Liverpool - Liverpool Hospital (5)
2065 - St Leonards - GenesisCare North Shore Private Hospital (4)
3000 - Melbourne - Peter MacCallum Cancer Centre (4)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (4)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (4)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (4)
4215 - Southport - Gold Coast University Hospital (4)
2109 - North Ryde - Macquarie University Hospital (3)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (3)
3128 - Box Hill - Box Hill Hospital - Eastern Health (3)
NZ.9016 - Dunedin - Dunedin Hospital (3)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (3)
3021 - St Albans - Western Health - Sunshine Hospital (3)
6150 - Murdoch - Fiona Stanley Hospital (3)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (3)
2217 - Kogarah - St George Hospital (2)
4102 - Woolloongabba - Princess Alexandra Hospital (2)
6005 - West Perth - Perth Blood Institute (2)
6168 - Cooloongup - Rockingham Hospital (2)
NZ.0622 - Takapuna - North Shore Hospital (2)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (2)
3630 - Shepparton - Goulburn Valley Health (2)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (2)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (2)
2500 - Wollongong - Wollongong Hospital (2)
6009 - Nedlands - One Clinical Research (2)
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit (2)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (2)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (2)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (2)
2031 - Randwick - Scientia Clinical Research Ltd (2)
2228 - Miranda - Southside Cancer Care Centre (2)
2031 - Randwick - Prince of Wales Hospital (2)
2640 - Albury - Albury Wodonga Regional Cancer Centre (2)
5042 - Bedford Park - Flinders Medical Centre (2)
2605 - Garran - The Canberra Hospital (2)
6000 - Perth - Royal Perth Hospital (2)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (2)
7000 - Hobart - Royal Hobart Hospital (2)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (2)
2480 - Lismore - Lismore Base Hospital (1)
2500 - Wollongong - Wollongong Private Hospital (1)
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre (1)
3844 - Traralgon - Latrobe Regional Hospital (1)
6009 - Nedlands - Linear Clinical Research (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
3690 - Wodonga - Border Medical Oncology at Wodonga Regional Cancer Centre (1)
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology (1)
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
4740 - Mackay - Mackay Base Hospital (1)
2305 - New Lambton Heights - John Hunter Children's Hospital (1)
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital (1)
NA
2485 - Tweed Heads - The Tweed Hospital (1)
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre (1)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (1)
2076 - Wahroonga - Sydney Adventist Hospital (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
3002 - East Melbourne - Epworth Freemasons (1)
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics (1)
4217 - Benowa - Pindara Private Hospital (1)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (1)
2487 - Cudgen - Tweed Valley Hospital (1)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (1)
2640 - Albury - Border Medical Oncology Research Unit (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
2086 - Frenchs Forest - Northern Beaches Hospital (1)
4032 - Chermside - The Prince Charles Hospital (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
Cancer Type
Cancer
Solid tumour
Haematological malignancy
Thoracic cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Multiple myeloma
Plasma cell disorder
B-cell lymphoma
B-cell malignancy
Lymphoma
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Gastrointestinal cancer
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Breast cancer
Urogenital cancer
Chronic lymphocytic leukaemia
Leukaemia
Lymphoid leukaemia
Small lymphocytic lymphoma
Adenocarcinoma
Carcinoma
Gastric cancer
Gastric carcinoma
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
Oesophageal cancer
Upper gastrointestinal cancer
Mantle cell lymphoma
Castrate-resistant prostate cancer
Male genital cancers
Prostate adenocarcinoma
Prostate cancer
Non-squamous non-small-cell lung cancer
Colorectal adenocarcinoma
Colorectal cancer
Lower gastrointestinal cancer
Rectal adenocarcinoma
Clear cell renal cell carcinoma
Kidney cancer
Head and neck cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy